Terence Flynn
Stock Analyst at Morgan Stanley
(4.49)
# 57
Out of 5,231 analysts
181
Total ratings
61.54%
Success rate
288.76%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Intellia Therapeutic... | Downgrades: Equal-Weight | 56 11 | 10.15 | 8.37% | 5 | Jan 27, 2025 | |
Johnson & Johnson | Maintains: Equal-Weight | 175 163 | 151.25 | 7.77% | 19 | Jan 23, 2025 | |
Merck & Co | Maintains: Equal-Weight | 123 113 | 98.17 | 15.11% | 15 | Jan 21, 2025 | |
AbbVie | Maintains: Overweight | 231 224 | 175.17 | 27.88% | 13 | Nov 12, 2024 | |
Bristol-Myers Squibb | Maintains: Underweight | 36 39 | 59.13 | -34.04% | 10 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 93 145 | 121.06 | 19.78% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 118 | 30.52 | 286.63% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 1106 1106 | 803.21 | 37.7% | 18 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 58 | 37.73 | 53.72% | 1 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 36 | 6.5 | 453.85% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 51 | 31.96 | 59.57% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 310 303 | 281.57 | 7.61% | 5 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 310 321 | 372.75 | -13.88% | 8 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 38 40 | 13.06 | 206.28% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 121 168 | 114.47 | 46.76% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 28 29 | 26.64 | 8.86% | 13 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 9 10 | 19.65 | -49.11% | 3 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 46 48 | 41.25 | 16.36% | 6 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 1 8 | 3.6 | 122.22% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 32 20 | 17.65 | 13.31% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 25 12 | 3.65 | 228.77% | 9 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 27 22 | 15.84 | 38.89% | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 2880 | n/a | n/a | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 246 436 | 144.44 | 201.86% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 35 | n/a | n/a | 1 | Jun 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 342 | 0.28 | 122042.86% | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Neutral | 54 | n/a | n/a | 3 | May 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | n/a | n/a | n/a | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 21, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Mar 13, 2017 |